Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INSP Stock Forecast 2026-2027
$44.26
Current Price
$1.31B
Market Cap
Buy 3
Hold 12
Sell 0
Wall St Analyst Ratings
Distance to INSP Price Targets
+46.9%
To High Target of $65.00
+20.9%
To Median Target of $53.50
+1.7%
To Low Target of $45.00
INSP Price Momentum
-21.9%
1 Week Change
-21.9%
1 Month Change
-70.7%
1 Year Change
-52.0%
Year-to-Date Change
-72.7%
From 52W High of $161.88
+0.6%
From 52W Low of $44.00
📊 TOP ANALYST CALLS
Did INSP Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Inspire is one of their latest high-conviction picks.
Latest INSP Stock Price Targets & Analyst Predictions
Based on our analysis of 22 Wall Street analysts, INSP has a neutral consensus with a median price target of $53.50 (ranging from $45.00 to $65.00). The overall analyst rating is Buy (7.2/10). Currently trading at $44.26, the median forecast implies a 20.9% upside. This outlook is supported by 3 Buy, 12 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jonathan Block at Stifel, projecting a 46.9% upside. Conversely, the most conservative target is provided by Shagun Singh at RBC Capital, suggesting a 1.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INSP Analyst Ratings
3
Buy
12
Hold
0
Sell
INSP Price Target Range
Low
$45.00
Average
$53.50
High
$65.00
Current: $44.26
Latest INSP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INSP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 5, 2026 | Mizuho | Anthony Petrone | Outperform | Maintains | $55.00 |
| May 5, 2026 | Baird | Mike Polark | Neutral | Maintains | $50.00 |
| May 5, 2026 | JP Morgan | Robbie Marcus | Neutral | Maintains | $54.00 |
| May 5, 2026 | Piper Sandler | Adam Maeder | Neutral | Downgrade | $55.00 |
| May 5, 2026 | Stifel | Jonathan Block | Buy | Maintains | $65.00 |
| May 5, 2026 | Truist Securities | Richard Newitter | Hold | Maintains | $50.00 |
| May 5, 2026 | Evercore ISI Group | Daniel Markowitz | Outperform | Maintains | $55.00 |
| May 5, 2026 | Wells Fargo | Larry Biegelsen | Equal-Weight | Maintains | $56.00 |
| May 5, 2026 | RBC Capital | Shagun Singh | Sector Perform | Maintains | $45.00 |
| Apr 15, 2026 | Truist Securities | Richard Newitter | Hold | Maintains | $64.00 |
| Apr 13, 2026 | Mizuho | Anthony Petrone | Outperform | Maintains | $70.00 |
| Apr 10, 2026 | Stifel | Jonathan Block | Buy | Maintains | $70.00 |
| Apr 6, 2026 | Evercore ISI Group | Daniel Markowitz | Outperform | Maintains | $62.00 |
| Mar 5, 2026 | Stifel | Jonathan Block | Buy | Maintains | $85.00 |
| Feb 13, 2026 | Wolfe Research | Mike Polark | Peer Perform | Downgrade | $N/A |
| Feb 12, 2026 | Baird | Mike Polark | Neutral | Downgrade | $74.00 |
| Feb 12, 2026 | Mizuho | Anthony Petrone | Outperform | Maintains | $85.00 |
| Feb 12, 2026 | Wells Fargo | Larry Biegelsen | Equal-Weight | Downgrade | $70.00 |
| Feb 12, 2026 | Jefferies | Michael Sarcone | Hold | Maintains | $66.00 |
| Feb 12, 2026 | Truist Securities | Richard Newitter | Hold | Maintains | $70.00 |
Inspire Medical Systems Inc (INSP) Competitors
The following stocks are similar to Inspire based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Inspire Medical Systems Inc (INSP) Financial Data
Inspire Medical Systems Inc has a market capitalization of $1.31B with a P/E ratio of 10.9x. The company generates $915.25M in trailing twelve-month revenue with a 14.3% profit margin.
Revenue growth is +1.6% quarter-over-quarter, while maintaining an operating margin of -0.5% and return on equity of +18.4%.
Valuation Metrics
Market Cap
$1.31B
Enterprise Value
$1.14B
P/E Ratio
10.9x
PEG Ratio
0.0x
Price/Sales
1.5x
Growth & Margins
Revenue Growth (YoY)
+1.6%
Gross Margin
+86.5%
Operating Margin
-0.5%
Net Margin
+14.3%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+22.3%
Current Ratio
6.3x
Debt/Equity
3.7x
ROE
+18.4%
ROA
+3.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Inspire Medical Systems Inc (INSP) Business Model
About Inspire Medical Systems Inc
What They Do
Develops innovative technology for sleep apnea treatment.
Business Model
The company commercializes the Inspire therapy, an implantable neurostimulation device for obstructive sleep apnea patients who struggle with CPAP devices. By offering a less invasive and patient-friendly alternative to traditional treatment methods, Inspire Medical Systems generates revenue through the sales of its medical devices and partnerships with healthcare providers.
Additional Information
Headquartered in Minnesota, the company aims to enhance sleep health management globally and emphasizes personalized, technologically advanced solutions in healthcare. Its innovative approach positions it well in the competitive medical device market.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
1,246
CEO
Mr. Timothy P. Herbert
Country
United States
IPO Year
2015
Website
www.inspiresleep.comInspire Medical Systems Inc (INSP) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Inspire (INSP) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Inspire (INSP) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
May 04, 2026
By Zacks Equity Research
Fundamental Analysis
Inspire Medical Systems (INSP) Q1 Earnings and Revenues Top Estimates
Inspire (INSP) delivered earnings and revenue surprises of +127.62% and +2.94%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
May 04, 2026
By Zacks Equity Research
Tale of the Tape
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
Pulmonx (LUNG) delivered earnings and revenue surprises of 0.00% and +2.52%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Apr 29, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Inspire Medical Systems' Q1 revenue rose only 1.6%, and 2026 guidance was cut by up to 10%. The company faces competition, reimbursement issues, and operational challenges.
Why It Matters
Inspire Medical Systems' stagnant revenue growth and lowered guidance indicate potential financial challenges, heightened competition, and operational issues, which could negatively impact stock performance.
Source: Seeking Alpha
Market Sentiment:
Negative
Quick Summary
INSP exceeded Q1 estimates but reduced its 2026 outlook due to reimbursement disruptions and challenges with the WISeR program impacting growth and procedure volumes.
Why It Matters
INSP's Q1 beat suggests short-term strength, but a downgraded 2026 outlook due to reimbursement issues and program challenges signals potential long-term growth risks.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Inspire Medical Systems, Inc. (INSP) held its Q1 2026 earnings call, detailing financial performance and business updates. Further specifics on earnings and forecasts were discussed.
Why It Matters
The Q1 2026 earnings call for Inspire Medical Systems provides insights into the company's financial health, growth potential, and market position, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Inspire Medical Systems (NYSE: INSP) announced financial results for Q1 2026, focusing on developing minimally invasive solutions for obstructive sleep apnea.
Why It Matters
Inspire Medical's quarterly financial results can indicate its growth potential and market performance, impacting stock valuation and investor confidence in the medical tech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Inspire (INSP) reported its revenue and EPS for Q1 2026; comparisons with Wall Street estimates and year-ago figures are advisable for a complete performance assessment.
Why It Matters
Comparing Inspire's revenue and EPS against Wall Street estimates and previous year figures can indicate growth trends and market expectations, influencing investor sentiment and stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Inspire Medical Systems (INSP) reported quarterly earnings of $0.10 per share, surpassing the Zacks Consensus Estimate of a loss of $0.36, unchanged from the prior year.
Why It Matters
Inspire Medical Systems' earnings beat expectations, indicating strong performance and potential growth, which can boost investor confidence and drive stock price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About INSP Stock
What is Inspire Medical Systems Inc's (INSP) stock forecast for 2026?
Based on our analysis of 22 Wall Street analysts, Inspire Medical Systems Inc (INSP) has a median price target of $53.50. The highest price target is $65.00 and the lowest is $45.00.
Is INSP stock a good investment in 2026?
According to current analyst ratings, INSP has 3 Buy ratings, 12 Hold ratings, and 0 Sell ratings. The stock is currently trading at $44.26. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INSP stock?
Wall Street analysts predict INSP stock could reach $53.50 in the next 12 months. This represents a 20.9% increase from the current price of $44.26. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Inspire Medical Systems Inc's business model?
The company commercializes the Inspire therapy, an implantable neurostimulation device for obstructive sleep apnea patients who struggle with CPAP devices. By offering a less invasive and patient-friendly alternative to traditional treatment methods, Inspire Medical Systems generates revenue through the sales of its medical devices and partnerships with healthcare providers.
What is the highest forecasted price for INSP Inspire Medical Systems Inc?
The highest price target for INSP is $65.00 from Jonathan Block at Stifel, which represents a 46.9% increase from the current price of $44.26.
What is the lowest forecasted price for INSP Inspire Medical Systems Inc?
The lowest price target for INSP is $45.00 from Shagun Singh at RBC Capital, which represents a 1.7% increase from the current price of $44.26.
What is the overall INSP consensus from analysts for Inspire Medical Systems Inc?
The overall analyst consensus for INSP is neutral. Out of 22 Wall Street analysts, 3 rate it as Buy, 12 as Hold, and 0 as Sell, with a median price target of $53.50.
How accurate are INSP stock price projections?
Stock price projections, including those for Inspire Medical Systems Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 9, 2026 3:02 AM UTC